Literature DB >> 15448930

[Current syphilis therapies and serological control. Commentary on the article by M. Hartmann in Hautarzt, Volume 2 (2004)].

H Heise1.   

Abstract

Penicillin is currently the drug of choice for therapy of syphilis. Clemizole and procaine penicillin are no longer available. For this reason only benzathine penicillin and infusion therapy with benzyl penicillin are possible. Treatment with doxycyline or ceftriaxone is also conceivable. Suitable serological methods are necessary to control the safety of the therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448930     DOI: 10.1007/s00105-004-0834-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  7 in total

1.  [Syphilis -- renaissance of a forgotten disease? A recommendation of the DSTDG for diagnosis and therapy].

Authors:  E Thoma-Greber
Journal:  Hautarzt       Date:  2003-12       Impact factor: 0.751

2.  [Current developments in syphilis. Prevention].

Authors:  U Marcus; W Kiehl; O Hamouda
Journal:  Hautarzt       Date:  2003-11       Impact factor: 0.751

3.  [Therapy of syphilis].

Authors:  M Hartmann
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

4.  1998 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-01-23

5.  [Comparison of various treatments of early syphilis in East Germany using CMT as therapy control].

Authors:  H Heise; D Doese
Journal:  Dermatol Monatsschr       Date:  1985

6.  [Treatment of early syphilis under conditions of penicillin intolerance].

Authors:  F Gilliet
Journal:  Schweiz Med Wochenschr       Date:  1975-01-04

7.  [Comparison of antisyphilitic therapy with penduran (benzathin-penicilline) and jenacillin A (author's transl)].

Authors:  H Heise; J H Rätz; S Fuchs
Journal:  Dermatol Monatsschr       Date:  1980-04
  7 in total
  1 in total

1.  Clemizole hydrochloride blocks cardiac potassium currents stably expressed in HEK 293 cells.

Authors:  Ling-Jun Jie; Wei-Yin Wu; Gang Li; Guo-Sheng Xiao; Shetuan Zhang; Gui-Rong Li; Yan Wang
Journal:  Br J Pharmacol       Date:  2017-01-12       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.